Search Results - chengfeng+merriman

4 Results Sort By:
A Novel mAb20-based In-cell ZnT8 Assay
Unmet Need: Prevalence of Type 2 Diabetes (T2D) continues to rapidly increase worldwide, contributing significant economic and global health burdens. There is an urgent need for the development of novel therapeutic strategies to treat T2D.Technical Details: Johns Hopkins researchers have identified a novel target to treat T2D and report here the development...
Published: 3/14/2025   |   Inventor(s): Dax Fu, Chengfeng Merriman
Keywords(s): Analytical Method, Diabetes, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, Metabolic Disorders, Proteomics/Immunoassays, Research Reagent, Target-based Screening Tool, Type II Diabetes
Category(s): Clinical and Disease Specializations > Diabetes > Type 2 Diabetes, Technology Classifications > Research Tools > Assays, Technology Classifications > Therapeutic Modalities > Targets
Highly Specific Monoclonal Antibodies used as Allosteric Inhibitors and Specific Biosensors of Human ZnT8
Unmet NeedType 2 diabetes (T2D) is a growing worldwide public health issue affecting over 500 million people while creating a $1 trillion economic burden on global healthcare economies. Many current and new therapeutics demonstrate varying degrees of effectiveness, but no single agent or combination thereof has been able to provide patients with lasting...
Published: 3/14/2025   |   Inventor(s): Dax Fu, Chengfeng Merriman
Keywords(s): Antibodies, Biologics, Diabetes, Discovery/Research Tools, Disease Indication, Metabolic Disorders, Monoclonal Antibodies, Research Reagent, Therapeutic Matter, Therapeutic Substance, Therapeutics, Translational Research Biomarker, Type II Diabetes
Category(s): Technology Classifications > Research Tools > Research Antibodies, Clinical and Disease Specializations > Diabetes > Type 2 Diabetes, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies
An ECL-based Autoantibody Assay for Early Diagnosis of T1D Using a Membrane-spanning ZnT8 Antigenic Domain
Unmet NeedApproximately 1.25 million people in the US have type 1 diabetes (T1D) and the rates of newly diagnosed cases in children are on the rise each year. T1D is caused by the development of an autoimmune reaction to pancreatic β cells. The first detectable sign of β cell autoimmunity is the appearance of diabetes-associated autoantibodies, which...
Published: 3/14/2025   |   Inventor(s): Dax Fu, Chengfeng Merriman, Liping Yu, Yong Gu
Keywords(s): Assay, Biomarker, Clinical Diagnostics, Diabetes, Diagnostic Biomarker, Diagnostic Tool, Disease Indication, In Vitro Diagnostics (Old), Measurement Tool, Metabolic Disorders, Type II Diabetes
Category(s): Clinical and Disease Specializations > Diabetes > Type 1 Diabetes, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics > In Vivo Diagnostics, Clinical and Disease Specializations > Diabetes > Type 2 Diabetes, Technology Classifications > Diagnostics > Diagnostic Biomarkers
Full-Length Znt8 Self-Antigen for Type 1 Diabetes Diagnosis
Unmet NeedType I diabetes (T1D) is an autoimmune disorder characterized by destruction of pancreatic beta-cells, leading to insulin deficiency and high blood glucose levels. In 2015, 1.3 million Americans had T1D, with approximately 1.5 million new cases of diabetes diagnosed each year. Despite advances in research, the incidence of T1D in children...
Published: 3/13/2025   |   Inventor(s): Dax Fu, Chengfeng Merriman, Hongjie Dai, Hao Wan
Keywords(s):  
Category(s): Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Clinical and Disease Specializations > Diabetes > Type 1 Diabetes
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum